Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
287 studies found for:    Open Studies | "Myeloproliferative Disorders"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Not yet recruiting Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders
Condition: Myeloproliferative Neoplasms
Intervention:
2 Recruiting Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
Condition: Chronic Myeloproliferative Neoplasms
Intervention: Drug: Givinostat
3 Recruiting Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms
Conditions: Myeloproliferative Disorders;   Pulmonary Hypertension
Intervention: Radiation: Radiology
4 Recruiting A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.
Conditions: Myeloproliferative Disease;   Pulmonary Hypertension
Intervention: Other: myeloproliferative disease
5 Recruiting Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
Conditions: Acute Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorders
Interventions: Other: Blood sampling;   Other: Bone marrow aspirate;   Other: Skin biopsy;   Other: Buccal swab
6 Not yet recruiting Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors in 3d Model Niche Endosteal
Condition: Myeloproliferative Disorders
Intervention:
7 Recruiting Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
Condition: Myeloproliferative Neoplasms
Interventions: Drug: Ruxolitinib;   Drug: Decitabine
8 Recruiting Familial Myeloproliferative Disorders
Conditions: Polycythemia Vera;   Essential Thrombocythemia;   Idiopathic Myelofibrosis
Intervention:
9 Recruiting Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Essential Thrombocythemia;   Myeloproliferative Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria;   Polycythemia Vera;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Primary Myelofibrosis;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
10 Recruiting PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
Conditions: Primary Myelofibrosis;   Myeloproliferative Disorders
Interventions: Procedure: Allogeneic hematopoietic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Drug: Ruxolitinib
11 Recruiting Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Pracinostat;   Behavioral: Questionnaire
12 Recruiting Italian Network MDS Registry
Condition: Myelodysplastic-Myeloproliferative Diseases
Intervention:
13 Recruiting Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML)
Conditions: Leukemia;   Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Decitabine
14 Recruiting Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms
Conditions: Myeloproliferative Neoplasms (MPN);   Polycythemia Vera (PV);   Essential Thrombocythemia (ET);   Myelofibrosis (MF)
Intervention: Procedure: Upper gastrointestinal endoscopy and Doppler ultrasound
15 Recruiting A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis
Conditions: Leukemia, Myelocytic, Acute;   Myelodysplastic Syndrome (MDS);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myelofibrosis
Intervention: Drug: CPI-0610
16 Recruiting Registry of Philadelphia-Negative Myeloproliferative Neoplasms
Condition: Hematologic Diseases
Intervention:
17 Recruiting Myeloproliferative Neoplasms (MPNs) Patient Registry
Conditions: Primary Myelofibrosis;   Polycythemia Vera;   Essential Thrombocythemia;   Mastocytosis;   Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;   Leukemia, Myelomonocytic, Juvenile;   Chronic Eosinophilic Leukemia-not Otherwise Specified;   Myelodysplastic-Myeloproliferative Diseases;   Neoplasms;   Leukemia, Myelomonocytic, Chronic
Intervention: Other: Observational
18 Not yet recruiting Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Biological: RNA sample of total leukocytes before start of treatment
19 Recruiting NK Cells to Prevent Disease Relapse for Patients High Risk Myeloid Malignancies
Conditions: Leukemia;   Myeloproliferative Diseases
Interventions: Drug: Melphalan;   Drug: Fludarabine;   Procedure: Expanded NK Cell Infusion;   Procedure: Bone Marrow Transplant;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Radiation: Total Body Irradiation (TBI)
20 Recruiting Study of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia
Condition: Leukemia
Intervention: Drug: Sotatercept

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.